S. Chhabra

P. Hari, M. Pasquini, M. Horowitz, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia.

M. Aljurf, J. Szer, R. Gale, 2019, Blood advances.

Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma

P. Hari, J. Zaucha, M. Krem, 2020, Cancer.

Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta‐analysis of phase 3 randomized controlled trials

P. Hari, S. Ghose, T. Smunt, 2020, Cancer.

Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improves Transplant Outcomes in Older MDS Patients.

M. Aljurf, J. Szer, R. Gale, 2021, Transplantation and cellular therapy.

Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.

M. Aljurf, R. Gale, K. Ballen, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Trends in the use of therapeutic plasma exchange in multiple myeloma

P. Hari, S. Janz, A. Szabo, 2020, Journal of clinical apheresis.

Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation.

M. Sorror, M. Krem, M. Pasquini, 2021, Transplantation and cellular therapy.

Incidence, Risk Factors for and Outcomes of Transplant-Associ- ated Thrombotic Microangiopathy

Saber, Marcelo, Edward, 2021 .

Incidence, Risk Factors for and Outcomes of Transplant‐Associated Thrombotic Microangiopathy

M. Aljurf, M. Pasquini, H. Lazarus, 2020, British journal of haematology.

Bronchoalveolar lavage-based COVID-19 testing in patients with cancer

M. Graham, B. George, B. Buchan, 2020, Hematology/Oncology and Stem Cell Therapy.

Optimal donor for African Americans with hematologic malignancy: HLA-haploidentical relative or umbilical cord blood transplant.

K. Ballen, O. Ringdén, D. Rizzieri, 2020, Biology of Blood and Marrow Transplantation.

Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome.

P. Hari, M. Pasquini, B. Shaw, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using total lymphoid irradiation and anti-thymocyte globulin conditioning

B. Efron, H. Kohrt, D. Miklos, 2015, Bone Marrow Transplantation.

Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure

J. Vose, Sonali M. Smith, R. Vij, 2018, Cancer.

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.

R. Gale, H. Khoury, U. Popat, 2018, Blood advances.

Phase 1/2 trial of Carfilzomib plus High Dose Melphalan Preparative Regimen for Salvage AHCT Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma

Giralt, P. Hari, H. Landau, 2020 .

Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma.

P. Hari, S. Giralt, H. Landau, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Arsenic trioxide and olanzapine co-administration: case analysis

M. Levitt, K. Kaufman, S. Chhabra, 2007, European Psychiatry.

Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield.

J. Wingard, T. Spitzer, B. Shaw, 2020, Blood advances.

Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes.

M. Pasquini, Stephanie J. Lee, B. Shaw, 2022, Transplantation and cellular therapy.

Impact of autologous blood transfusion after bone marrow harvest on unrelated donor’s health and outcome: a CIBMTR analysis

M. Norkin, J. Wingard, J. Liesveld, 2020, Bone Marrow Transplantation.

Monoclonal Gammopathies After Renal Transplantation: A Single-center Study.

P. Hari, A. Szabo, R. Wu, 2020, Clinical lymphoma, myeloma & leukemia.

Comparison of high doses of total body irradiation in myeloablative conditioning prior to hematopoietic cell transplantation.

M. Perales, E. Guinan, S. Mineishi, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era

P. Hari, Shaji K. Kumar, R. Gale, 2020, Leukemia.

African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States

S. Jagannath, R. Vij, P. Hari, 2020, Cancer.

Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.

R. Vij, D. Lad, M. Perales, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

P. Hari, D. Madduri, J. Castillo, 2020, Leukemia & lymphoma.

Primary refractory multiple myeloma: a real-world experience with 85 cases

R. Vij, P. Hari, A. Nooka, 2020, Leukemia & lymphoma.

Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma

P. Hari, M. Krem, Shaji K. Kumar, 2020, British journal of haematology.

Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups.

P. Hari, R. Kyle, Shaji K. Kumar, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European S

M. Aljurf, R. Gale, N. Callander, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT

M. Aljurf, R. Gale, N. Callander, 2019, Bone Marrow Transplantation.

Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis

P. Hari, M. Pasquini, D. Weihrauch, 2017, Contemporary clinical trials communications.

Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury–Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant

M. Ardura, V. Brown, M. Perales, 2020, JAMA network open.

Anterior Mediastinal Mass in a Young Marijuana Smoker: A Rare Case of Small-Cell Lung Cancer

S. Jabbour, S. Chhabra, J. Kothadia, 2012, Case reports in medicine.

Autonomic nervous system control of multiple myeloma.

P. Hari, S. Janz, A. D’Souza, 2020, Blood reviews.

Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies

R. Vij, P. Hari, M. Liedtke, 2021, Leukemia.

Second primary malignancy after multiple myeloma‐population trends and cause‐specific mortality

P. Hari, S. Bhatia, R. Cornell, 2018, British journal of haematology.

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

R. Vij, P. Hari, M. Liedtke, 2019, Leukemia.

Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation

E. Estey, B. Sandmaier, M. Krem, 2021, Bone Marrow Transplantation.

Monoclonal gammopathy of renal significance (MGRS): Real‐world data on outcomes and prognostic factors

H. Einsele, E. Zamagni, D. Coriu, 2022, American journal of hematology.

Exploring health behaviors and the feasibility of a lifestyle intervention for patients with multiple myeloma

Patricia M Sheean, P. Hari, K. Flynn, 2022, Supportive Care in Cancer.

Multiple myeloma and COVID-19

P. Hari, A. D’Souza, S. Chhabra, 2020, Leukemia.

Rap1A, Rap1B, and β-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol

Carol L. Williams, P. Hari, A. Szabo, 2022, The Yale journal of biology and medicine.

An updated single center experience with plerixafor and granulocyte colony‐stimulating factor for stem cell mobilization in light chain amyloidosis

P. Hari, Bryon D Johnson, A. Szabo, 2019, Journal of clinical apheresis.

Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning.

M. Norkin, S. Mineishi, M. Krem, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation

Sonali M. Smith, M. Perales, Q. Bashir, 2016, British journal of haematology.

Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma

M. Lunning, B. Holkova, A. Chari, 2018, Leukemia & lymphoma.

Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma

M. Lunning, R. Stuart, A. Chari, 2020, Hematological Oncology.

Utilization and cost implications of hematopoietic progenitor cells stored for a future salvage autologous transplantation or stem cell boost in myeloma patients.

P. Hari, M. Pasquini, Bryon D Johnson, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT

H. Greinix, Z. DeFilipp, D. Kelly, 2018, Bone Marrow Transplantation.

Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation.

M. Norkin, M. Aljurf, J. Wingard, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Relapse after allogeneic hematopoietic cell transplantation for multiple myeloma: Survival outcomes and factors influencing them.

P. Hari, M. Pasquini, A. Szabo, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery

K. Sullivan, D. Rizzieri, A. Sung, 2016, Journal of Hematology & Oncology.

Alpha‐1‐antitrypsin for the treatment of steroid‐refractory acute gastrointestinal graft‐versus‐host disease

P. Hari, M. Pasquini, B. Shaw, 2017, American journal of hematology.

Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective

P. Hari, M. Pasquini, B. Shaw, 2018, Bone Marrow Transplantation.

Age is no Barrier for Adults undergoing HCT for AML in CR1: Contemporary CIBMTR Analysis

C. Hourigan, S. Farag, V. Bhatt, 2022, Bone Marrow Transplantation.

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis.

R. Soiffer, M. Grunwald, N. Ghosh, 2021, Blood.

Collection of Peripheral Blood Progenitor Cells in One Day is Associated with Decreased Donor Toxicity compared to Two Days in Unrelated Donors.

J. Wingard, J. Liesveld, T. Spitzer, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Current Use and Trends in Hematopoietic Cell Transplantation in the United States.

P. Hari, M. Pasquini, M. Horowitz, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy

P. Hari, N. Ledeboer, M. Hamadani, 2021, Blood.

Kahn JM, Brazauskas R, Tecca HR, et al. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Adv. 2020;4(9):2084-2094.

M. Norkin, B. George, R. Gale, 2020, Blood advances.

Predictors of lost to follow-up among pediatric and adult hematopoietic cell transplant survivors: A report from the Center for International Blood and Marrow Transplant Research.

W. Wood, M. Aljurf, A. Yoshimi, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Letter to the Editor Regarding “Diagnostic Considerations for COVID-19 in Recipients of Allogeneic Hematopoietic Cell Transplantation”

M. Graham, P. Hari, B. Shaw, 2020, Biology of Blood and Marrow Transplantation.

BACTERIAL BLOOD STREAM INFECTIONS (BSI), PARTICULARLY POST-ENGRAFTMENT BSI, ARE ASSOCIATED WITH INCREASED MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

G. Papanicolaou, V. Brown, M. Aljurf, 2018, Bone Marrow Transplantation.

Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis

M. Horowitz, B. Shaw, S. Devine, 2020, Biology of Blood and Marrow Transplantation.

Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

M. Krem, C. Hourigan, M. Aljurf, 2021, Blood advances.

Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies

B. Savani, M. Hamadani, S. Chhabra, 2021, British journal of haematology.

Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.

H. Kohrt, P. Lavori, D. Miklos, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pretransplant Splenic Irradiation in Patients With Myeloproliferative Neoplasms

P. Hari, S. Firat, S. Chhabra, 2022, Advances in radiation oncology.

Laboratory Mice – A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma

F. Zhan, P. Hari, S. Janz, 2021, Frontiers in Immunology.

Salvage second transplantation in relapsed multiple myeloma

P. Hari, A. D’Souza, S. Chhabra, 2020, Leukemia.

Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation.

P. Hari, M. Pasquini, N. Shah, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase 1 trial of SGN‐CD70A in patients with CD70‐positive, metastatic renal cell carcinoma

David C. Smith, N. Vogelzang, S. Pal, 2019, Cancer.

A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma

David C. Smith, K. Kolibaba, T. Phillips, 2018, Investigational New Drugs.

Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis

L. Castagna, Fei Wan, M. Arango, 2021, Bone Marrow Transplantation.

Non-infectious pulmonary toxicity after allogeneic hematopoietic cell transplantation.

M. Sorror, M. Krem, M. Pasquini, 2022, Transplantation and cellular therapy.

Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.

P. Hari, S. Tarima, A. D’Souza, 2021, Clinical lymphoma, myeloma & leukemia.

Engraftment

S. Chhabra, P. Hari, L. Runaas, 2021, Blood and Marrow Transplant Handbook.

Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis

P. Hari, B. Shaw, A. Szabo, 2019, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation.

R. Vij, M. Aljurf, R. Gale, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.

Sonali M. Smith, M. Perales, R. Gale, 2016, Blood.

The effect of G-CSF use on hospital length of stay after an allogeneic hematopoietic cell transplantation: a retrospective multicenter cohort study.

M. Eapen, S. Chhabra, G. George, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis.

R. Soiffer, M. Grunwald, N. Ghosh, 2021, Blood.

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States.

W. Wood, M. Sorror, F. Baron, 2017, Blood.

Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation.

P. Hari, M. Pasquini, A. Szabo, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients

N. Ledeboer, A. D’Souza, N. Shah, 2022, Cancer Cell.

Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT.

M. Aljurf, R. Gale, J. Pidala, 2020, Journal of Clinical Oncology.

Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis

B. Gyawali, P. Hari, A. Szabo, 2018, JAMA oncology.

Randomized Multicenter Trial of Sirolimus vs. Prednisone as Initial Therapy for Standard Risk Acute GVHD: BMT CTN 1501.

E. Leifer, M. Horowitz, J. Pidala, 2019, Blood.

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

P. Hari, N. Callander, E. Medvedova, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial

P. Hari, N. Callander, E. Medvedova, 2021, Blood.

Predicting mortality after autologous transplant: Development of a novel risk score.

C. Solano, B. Shaw, A. Sureda, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time.

M. Norkin, J. Szer, J. Liesveld, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.

R. Vij, M. Aljurf, R. Gale, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Direct HLA Genetic Comparisons Identify Highly Matched Unrelated Donor-Recipient Pairs with Improved Transplantation Outcome.

Binod Dhakal, Matthew W. Anderson, Ibrahim Y. Vazirabad, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

P. Hari, N. Callander, E. Medvedova, 2019, Blood.

Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting.

P. Hari, M. Pasquini, B. Shaw, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation.

A. Krishnan, P. Hari, J. Richter, 2020, Clinical lymphoma, myeloma & leukemia.

Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era

P. Hari, Shaji K. Kumar, R. Gale, 2021, Leukemia.

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report

J. Mehta, M. Perales, N. Saba, 2019, Clinical Cancer Research.

Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries.

E. Guinan, M. Aljurf, M. Pasquini, 2020, Biology of Blood and Marrow Transplantation.

Thrombotic thrombocytopenic purpura precipitated by thyrotoxicosis

S. Chhabra, Grace C. Tenorio, 2012, Journal of clinical apheresis.

Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma

P. Hari, M. Pasquini, A. D’Souza, 2019, Blood Cancer Journal.

Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia.

J. Liesveld, Z. DeFilipp, B. Shaw, 2020, Blood advances.

Expanded HCT-CI Definitions Capture Comorbidity Better for Younger Patients of Allogeneic HCT for Non-Malignant Diseases

M. Sorror, E. Guinan, M. Krem, 2022, Transplantation and Cellular Therapy.

Inferior Outcomes with Cyclosporine and Mycophenolate mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation.

M. Aljurf, R. Gale, J. Pidala, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics

S. Chhabra, 2017, Pharmaceuticals.

Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation.

M. Pasquini, A. D’Souza, N. Shah, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies.

P. Hari, A. Szabo, A. D’Souza, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma

L. Staudt, W. Wilson, S. de Vos, 2021, Leukemia & lymphoma.

Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma

S. Chhabra, B. Dhakal, M. Mohan, 2022, JAMA network open.

Diffuse large B‐cell lymphoma with primary treatment failure: Ultra‐high risk features and benchmarking for experimental therapies

Zheng Zhou, C. Flowers, A. Evens, 2017, American journal of hematology.

Severity of cytokine release syndrome and its association with infections after T-cell replete haploidentical related donor transplantation.

M. Graham, P. Hari, M. Pasquini, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma

P. Hari, A. D’Souza, S. Chhabra, 2021, Blood advances.

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

M. Liedtke, Shaji K. Kumar, O. Oluwole, 2023, Nature Medicine.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in T-cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research.

J Wagner, F. Awan, M. Krem, 2022, Transplantation and cellular therapy.

Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma.

P. Hari, R. Gale, Y. Nieto, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cyclosporine in Combination with Mycophenolate Mofetil Leads to Increased Incidence of Graft-Versus-Host Disease and Inferior Outcomes after Myeloablative Allogeneic Hematopoietic Cell Transplantation: A CIBMTR Analysis

Y. Liu, J. Pidala, O. Ringdén, 2018 .

Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial

P. Hari, M. Pasquini, D. Weihrauch, 2020, EClinicalMedicine.

Fludarabine/busulfan conditioning based allogeneic hematopoietic cell transplantation for myelofibrosis: Role of ruxolitinib in improving survival outcomes.

P. Hari, M. Pasquini, B. Shaw, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades.

P. Hari, R. Gale, Y. Nieto, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Graft Failure

S. Chhabra, P. Hari, L. Runaas, 2021, Blood and Marrow Transplant Handbook.

Pre-transplant marital status and hematopoietic cell transplantation outcomes.

W. Wood, K. Sullivan, M. Aljurf, 2020, Current oncology.

Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals.

P. Hari, M. Pasquini, A. Szabo, 2019, JAMA network open.

Survival outcomes of allogeneic hematopoietic cell transplants with EBV‐positive or EBV‐negative post‐transplant lymphoproliferative disorder, A CIBMTR study

P. Hari, V. Brown, H. Heslop, 2019, Transplant infectious disease : an official journal of the Transplantation Society.

A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma

P. Hari, D. Madduri, J. Castillo, 2020, American journal of hematology.

Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.

A. Jakubowiak, Sharmila Patel, J. Laubach, 2022, Transplantation and cellular therapy.

Impact of autologous hematopoietic cell transplantation on disease burden quantified by next‐generation sequencing in multiple myeloma treated with quadruplet therapy

P. Hari, N. Callander, E. Medvedova, 2022, American journal of hematology.

R. Stuart, L. Costa, S. Chhabra, 2014, Transfusion.

Title: Impact of Induction Therapy with VRD vs. VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.

Shaji K. Kumar, M. Aljurf, M. Qazilbash, 2021, Transplantation and cellular therapy.

Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.

S. Jagannath, R. Vij, P. Hari, 2021, Clinical lymphoma, myeloma & leukemia.

Differential use of the hematopoietic cell transplantation-comorbidity index among adult and pediatric transplant physicians

M. Sorror, M. Pasquini, M. Thakar, 2022, Leukemia & lymphoma.

Impact of type of reduced‐intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma

N. Ghosh, M. Cairo, U. Farooq, 2020, British journal of haematology.

Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy

S. Janz, M. Zangari, F. van Rhee, 2022, Bone Marrow Transplantation.

Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin

Zheng Zhou, C. Flowers, A. Evens, 2018, Leukemia & lymphoma.

C‐MYC–positive relapsed and refractory, diffuse large B‐cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy

Zheng Zhou, C. Flowers, F. Hernandez-Ilizaliturri, 2017, Cancer.

Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

S. Jagannath, D. Siegel, P. Hari, 2021, Blood.

Multicenter Phase 1b Dose-Escalation Study of Ibrutinib and Lenalidomide Combined with Dose-Adjusted EPOCH-R in Patients with Relapsed/Refractory DLBCL

L. Staudt, W. Wilson, T. Phillips, 2015 .

Prevalence and Significance of Sarcopenia in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

P. Hari, S. Janz, A. Szabo, 2020, Bone Marrow Transplantation.

Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease.

P. Hari, A. Szabo, A. D’Souza, 2019, Hematology/oncology and stem cell therapy.

Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination

Nicholas R. Waters, P. Hari, M. V. D. van den Brink, 2022, medRxiv.

Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

J. Burke, J. Leonard, A. Krishnan, 2020 .

Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial

P. Hari, N. Callander, E. Medvedova, 2022, Blood.

Zirconia in dental implantology: A review

P. Eachempati, S. Chhabra, Abhishek Apratim, 2015, Journal of International Society of Preventive & Community Dentistry.

Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.

M. Liedtke, Shaji K. Kumar, O. Oluwole, 2023, Nature medicine.

The Transplant Ecosystem: A New Concept to Improve Access and Outcomes for Older Allogeneic Hematopoietic Cell Patients.

Shannon R. McCurdy, D. Howard, R. Jayani, 2023, Transplantation and cellular therapy.

High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma

Sandeep Jain, C. Wallace, Bei Liu, 2015, Journal of Hematology & Oncology.

Autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (MM) in the era of novel agents: A meta-analysis of phase III randomized controlled trials.

P. Hari, J. Jackson, S. Usmani, 2017 .

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

J. Burke, J. Leonard, A. Krishnan, 2019, Blood.

Adapting the HCT-CI Definitions for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation.

M. Sorror, M. Krem, M. Pasquini, 2022, Transplantation and Cellular Therapy.

Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation

P. Hari, M. Horowitz, S. Cole, 2018, BMC cancer.

Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi‐institutional experience

A. Lesokhin, R. Orlowski, M. Zangari, 2022, American journal of hematology.

Overall survival of patients with triple‐class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH

S. Jagannath, S. Lonial, D. Siegel, 2020, American journal of hematology.

Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies

A. Jakubowiak, Sharmila Patel, J. Laubach, 2021, Blood.

Adenocarcinoma associated with tail gut cyst.

E. Poplin, S. Chhabra, C. Rezac, 2012, Journal of gastrointestinal oncology.

Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies

S. Jagannath, S. Lonial, D. Siegel, 2019, Blood.

Corneal toxicity with belantamab mafodotin: Multi‐institutional real‐life experience

S. Janz, M. Zangari, A. Szabo, 2022, American journal of hematology.

Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease

P. Hari, N. Shah, M. Hamadani, 2019, Leukemia & lymphoma.

Corrigendum to 'Current Use and Trends in Hematopoietic Cell Transplantation in the United States' [Transplantation and Cellular Therapy 26/8 (2020) e177-e182].

P. Hari, M. Pasquini, M. Horowitz, 2021, Transplantation and Cellular Therapy.

Latest Advances in Concepts and Treatment Protocols of Dental Implants: A Brief Review

Hasan Sarfaraz, Saurabh Chhabra, S. Chhabra, 2011 .

THE ESSENTIALS OF CHRONOPHARMACOTHERAPEUTICS

S. Chhabra, 2012 .

Graft-versus-host disease (GVHD) risk with daratumumab (Dara) therapy post allogeneic transplantation (alloHCT) for multiple myeloma (MM).

A. Krishnan, P. Hari, J. Richter, 2018 .

A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma

David C. Smith, K. Kolibaba, T. Phillips, 2018, Investigational New Drugs.

Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies

P. Hari, T. Fenske, S. Chhabra, 2022, Clinical Lymphoma Myeloma and Leukemia.

Correction: Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT

M. Aljurf, R. Gale, N. Callander, 2019, Bone Marrow Transplantation.

Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma.

S. Jagannath, R. Vij, P. Hari, 2021 .

Propylene glycol (PG)-free melphalan versus PG-melphalan as conditioning for autologous hematopoietic cell transplantation for myeloma.

P. Hari, M. Pasquini, A. Szabo, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Breaking the Age Barrier: Physicians' Perceptions on Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults.

W. Wood, M. Sorror, D. Howard, 2021, Transplantation and cellular therapy.

Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.

Sonali M. Smith, M. Perales, R. Gale, 2016, Blood.

Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients.

A. D’Souza, N. Shah, M. Hamadani, 2022, Clinical lymphoma, myeloma & leukemia.

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.

U. Popat, M. Kalaycio, Z. DeFilipp, 2018, Blood advances.

Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation

W. Saber, M. Hamadani, T. Fenske, 2024, Bone marrow transplantation.

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.

P. Hari, E. Medvedova, R. Cornell, 2023, The Lancet. Haematology.